BIO Notebook, Day 1: Janssen, Boehringer And More Talk Deals, Pipeline Progress And Investment
Scrip begins its week at the BIO International Convention with interviews and panel discussions about dealmaking and progressing development pipelines. Among the first day highlights: Janssen's hunt for technology, Boehringer's NASH plans and rising investment in neuroscience.
You may also be interested in...
Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts. At BIO, he outlined his strategy and goals.
Allergan CEO Brent Saunders, speaking at the BIO International Convention on June 19, said the biopharma industry needs to improve its image before its defenders in Congress bow to public pressure on drug pricing concerns.
Novartis CEO Jimenez suggests Trump Administration may help remove regulatory barriers to US outcome-based contracting between manufacturers and payers; Duke Margolis Center for Health Policy plans policy initiative to promote value-based purchasing for drugs, medical devices and gene therapy.